The Stock Ticker Notable Investors Are Holding

They may not be trading on public markets, but Pacaso just reserved the ticker PCSO. Co-founded by the man who took Zillow from seed to IPO, Pacaso brings co-ownership to a $1.3T market. They've earned $110M+ in gross profits already. Well-known firms like Maveron even invested.

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

Vandana Singh
May 06, 2025

Neurocrine Biosciences Inc. (NASDAQ:NBIX) stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings.

The company on Monday reported adjusted EPS of 70 cents, lower than the $1.20 reported a year ago, beating the consensus of 54 cents.

Neurocrine reported sales of $572.6 million compared to $515.3 million a year ago, missing the consensus of $559.3 million.

Ingrezza’s first-quarter 2025 net product sales were $545 million, representing an 8% year-over-year growth, driven by underlying patient demand, including record new patient starts and improved gross-to-net dynamics.

  • Expanded formulary access for Ingrezza significantly improved coverage to include two-thirds of tardive dyskinesia (TD) and Huntington’s disease Medicare beneficiaries.
  • William Blair writes, “Ingrezza sales for the quarter were more resilient than investors had feared given Part D formulary utilization and Teva Pharmaceutical Industries Ltd’s (NYSE:TEVA) Austedo competition.”

Also Read: Neurocrine Biosciences’ Positive Crenessity Physician Survey Turns This Analyst Bullish

Crenessity first-quarter net product sales were $14.5 million and included 413 total patient enrollment start forms, reflecting strong initial patient demand with approximately 70% reimbursement coverage for dispensed scripts.

Guidance: Neurocrine Biosciences reaffirms its 2025 Ingrezza sales guidance of $2.5 billion-$2.6 billion.

Despite headwinds, Ingrezza sales “avoided a big miss,” William Blair analyst Myles R. Minter said in a Tuesday research note.

Minter views Ingrezza as “the gold-standard pharmacotherapy for TD, given its once-daily dosing, no need for long dose titration intervals, and lack of a suicidality and depression FDA black-box warning.” In addition, the company boasts 14 years of potential future patent protection.

“We also view the beat from Crenessity as indicative of a strong sales effort, and although early, we are impressed by the early launch metrics and interest in the orphan disease therapy,” Minter added.

William Blair maintains the Outperform rating.

Other analyst reaction:

  • Needham maintains Neurocrine Biosciences with a Buy, raising the price target from $138 to $139.
  • Canaccord Genuity maintains Neurocrin with a Buy, raising the price target from $158 to $160.
  • UBS keeps the Buy rating for Neurocrine, raising the price target from $137 to $152.
  • BMO Capital maintains Neurocrine with a Market Perform, raising the price target from $96 to $115.
  • Guggenheim maintains Neurocrine with a Buy, raising the price target from $155 to $165.

Price Action: NBIX stock is up 14% at $125.07 at the last check Tuesday.

Read Next:

  • Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

Continue Reading...

Popular

Mark Cuban Reacts to Elon Musk-Donald Trump Feud

The escalating public feud between Elon Musk and President Trump has prompted a response from Mark Cuban.

The Next Palantir? Does This Under $5 AI Stock Have The Potential To Rise And Shine

This micro-cap AI stock is being increasingly touted as the next Palantir Technologies Inc. (NASDAQ: PLTR), but some analysts disagree with this framing.

Former Zillow Execs Target $1.3T Market - Ad

One co-founded Zillow. The other sold his company to Zillow for $120M. Now they're transforming a $1.3T market via co-ownership. Pacaso's already earned $110M+ in gross profit and reserved the Nasdaq ticker PCSO.

Federal judge blocks Trump's firing of Consumer Product Safety Commission members

BALTIMORE (AP) — A federal judge has blocked the terminations of three Democratic members of the Consumer Product Safety Commission after they were fired by President Donald Trump in his effort to assert over independent federal agencies.

Trump's 'Numbskull' Insult Comes Back To Bite—In Record Time

Oil prices surged after Israel's airstrikes on Iran, reigniting inflation fears and complicating Trump's push for rate cuts. Powell's caution now seems more justified.

The Father-Son Duo Revolutionizing Homebuilding - Ad

Paolo and Galiano Tiramani founded BOXABL with a disruptive idea: bring factory efficiency to homebuilding. Today, new homes can roll off their assembly lines in ~4 hours - with 700+ built already. Now, they're prepping for Phase 2, combining modules into larger homes and apartments.

Appeals court hands AP an incremental loss in its attempt to regain its access to Trump events

Digging deep into free-speech precedents in recent American history, a federal appeals panel handed The Associated Press an incremental loss on Friday in its continuing battle with the Trump administration over access by its journalists to cover presidential events.

A Better Hedge Than Gold? - Ad

While the whole world is piling into gold as a hedge... White House documents reveal Trump is betting big on a completely under-the-radar resource. This little-known resource is minting 1,600 millionaires every single day... And investors have a rare opportunity to take advantage before everyone else catches on.

IonQ Buys Oxford Ionics In $1.075 Billion Deal To Supercharge Quantum Tech

IonQ to acquire Oxford Ionics for $1.075 billion, combining their quantum computing technologies to deliver powerful and innovative systems.

How To Build a Home in Nearly 4 Hours - Ad

The U.S. is short 2.3M homes, making affordable, efficient housing critical. BOXABL brought assembly lines to construction, building homes in hours, not months. With 700+ built and one of America's largest homebuilders as an investor and partner, they're growing fast.

Warren Buffett Makes Over $2.2 Million A Day From This Stock

Warren Buffett's Berkshire Hathaway is set to earn $816 million in Coca-Cola dividends in 2025.

Gold Just Hit Another Record. This Junior Could Be Next. - Ad

This copper junior was the smallest company invited to a top global mining conference. With nearly 1B pounds CuEq and 50,000m of funded drilling, this story won't stay quiet for long.

How to Hack a $1.3T Market - Ad

Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.

JPMorgan To Accept Crypto-Linked ETFs As Loan Collateral

JPMorgan Chase (NASDAQ:JPM) is preparing to allow clients in its trading and wealth management divisions to use certain cryptocurrency-

Nvidia Stock Seen As 'Unique Opportunity' Amid Chip Sector Volatility, Says Morgan Stanley: 'We Are Materially Under Shipping Demand'

Morgan Stanley has reaffirmed its Overweight rating on Nvidia Corporation (NASDAQ: NVDA), keeping the company as its top choice, despite broader concerns about the semiconductor sector.

Why BlackRock is Hoarding 6X More Bitcoin Than Miners Produce - Ad

A Bitcoin supply shock is building. Institutions and ETFs are buying faster than miners can keep up - creating a shortage most investors haven't noticed. If Bitcoin hits $300K, altcoins could explode 1,000%+. We wrote Crypto Revolution to help you prepare.

First direct flight from US to Greenland since 2008 lands on Trump's birthday

NUUK, Greenland (AP) — The first direct flight from the U.S. to Greenland by an American airline landed in the capital city of Nuuk on Saturday.

ABC's Terry Moran is suspended following his social media post calling Trump and Miller haters

NEW YORK (AP) — ABC News has suspended correspondent Terry Moran for calling Trump administration deputy chief of staff a “world class hater” in a since-deleted social media post.

How high will Bitcoin go in 2025? - Ad

A new coin is emerging in the crypto bull market. Investing now could be like buying Bitcoin in 2013. Before it took off. Or scooping up Ethereum in 2017.. before it soared.

Musk vs. Trump: Tesla Slashes Cybertruck Prices After Feud Heats Up, Here's How Much You Need To Pay for It Now

In the wake of the public disagreement between Elon Musk and President Trump, Tesla has declared significant price reductions for its Cybertruck model.

Is Elon's Empire Crumbling? - Ad

Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after July 23rd, it may be too late.

Stock Of The Day: Could Lucid Gaps Refill?

If a stock gaps through certain price levels, then eventually reverses and gets back to these same levels, it may gap back through them.

The Stock Ticker Notable Investors Are Holding - Ad

They may not be trading on public markets, but Pacaso just reserved the ticker PCSO. Co-founded by the man who took Zillow from seed to IPO, Pacaso brings co-ownership to a $1.3T market. They've earned $110M+ in gross profits already. Well-known firms like Maveron even invested.

Circle's Flagship Stablecoin USDC Set For Rapid Growth, Analyst Says Regulatory Climate Key

Circle stock surges as analyst initiates coverage with Buy rating and $235 price target, predicting growth in stablecoin adoption, stablecoin market cap, and Circle's revenue and EPS by 2026.

Former Zillow Execs Target $1.3T Market - Ad

One co-founded Zillow. The other sold his company to Zillow for $120M. Now they're transforming a $1.3T market via co-ownership. Pacaso's already earned $110M+ in gross profit and reserved the Nasdaq ticker PCSO.

Takeaways from AP's report on the business interests of Trump's surgeon general pick

PROVIDENCE, R.I. (AP) — President Donald Trump’s pick to be U.S. surgeon general has repeatedly said the nation’s medical and food systems are corrupted by special interests and people out to make a profit at the expense of Americans’ health. Yet as has criticized scientists, medical schools and regulators for taking money from the food and pharmaceutical industries, she has promoted dozens of products in ways that put money in her own pocket.

Cathie Wood Dumps $1.8 Million In Coinbase Stock As Bitcoin Nears $110K All-Time High

On Monday, Cathie Wood-led Ark Invest made a notable move by selling shares of Coinbase Global Inc. (NASDAQ:COIN) across its ETFs.

The Father-Son Duo Revolutionizing Homebuilding - Ad

Paolo and Galiano Tiramani founded BOXABL with a disruptive idea: bring factory efficiency to homebuilding. Today, new homes can roll off their assembly lines in ~4 hours - with 700+ built already. Now, they're prepping for Phase 2, combining modules into larger homes and apartments.

Trump's Truth Social Files For Bitcoin ETF As Family Goes 'Seriously Long' On Crypto

The New York Stock Exchange submitted a Bitcoin (CRYPTO: BTC) exchange-traded filing Tuesday on behalf of Truth Social, the social media platform owned by President Donald Trump.

A Better Hedge Than Gold? - Ad

While the whole world is piling into gold as a hedge... White House documents reveal Trump is betting big on a completely under-the-radar resource. This little-known resource is minting 1,600 millionaires every single day... And investors have a rare opportunity to take advantage before everyone else catches on.

Truck units of Toyota and Daimler reach merger deal, first announced two years ago

TOKYO (AP) — The truck divisions of Japan’s Toyota and Daimler of Germany have agreed to merge to form “a new strong Japanese truck powerhouse” to work together in vehicle development, procurement and production.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright activatrade.ca
Privacy Policy | Terms of Service